New hope for treating a rare genetic disorder

‘Bench to bedside’ research at OHSU may lead to treatment for ALD

By Erik Robinson March 29, 2017 Portland, Ore.

Downloads

Tom Scanlan, Ph.D. a professor of physiology and pharmacology in the OHSU School of Medicine, March 10, 2017. (OHSU/Kristyna Wentz-Graff)

Meredith Hartley, Ph.D.

Meredith D. Hartley, Ph.D., March 10, 2017. (OHSU/Kristyna Wentz-Graff)

ALD research

Tom Scanlan, Ph.D. (left) and Meredith D. Hartley, Ph.D. are researching a synthetic thyroid hormone that might possibly help stop the progression of the neurodegenerative disease adrenoleukodystrophy, or ALD. (OHSU/Kristyna Wentz-Graff)

ALD research

Tom Scanlan, Ph.D. (left) and Meredith D. Hartley, Ph.D. look over data on March, 10, 2017, part of their research on a synthetic thyroid hormone that might possibly help stop the progression of the neurodegenerative disease adrenoleukodystrophy, or ALD. (OHSU/Kristyna Wentz-Graff)